Document Detail

Gonadotropin releasing hormone agonist therapy and its effect on bone mass.
MedLine Citation:
PMID:  1910246     Owner:  NLM     Status:  MEDLINE    
The effects on bone mass of a 6 month therapeutic cycle with a gonadotropin releasing hormone agonist (GnRHa) were studied in 22 patients, ten affected by pelvic endometriosis and 12 by uterine fibroids. All patients were subjected to preliminary full examinations to confirm their diagnosis (laparoscopy for the endometriosis group and precise ultrasound volume measurements for uterine fibroids group). Before the beginning of treatment, bone mineral density (BMD) was measured in each patient both on the distal third of the forearm, with single-photon absorptiometry, and on the lumbar spine (L1-L4), with dual photon absorptiometry. The gonadotropin releasing hormone agonist used was buserelin. In the first week of therapy 0.5 mg of the drug was administered subcutaneously thrice daily. In the following 25 weeks the same drug was given intranasally, at a dosage of 300 micrograms again three times a day. Bone mass measurements, both at the peripheral and at the axial site, were repeated at the end of the 26-week therapeutic cycle and then again 6 months later. At the 26th week, a significant decrease of BMD was observed at both sites. The loss was 1.5% (p less than 0.05) on the lumbar spine, and 2.1% (p less than 0.05) on the radius. No bone mass restoration took place in the following 6 months. On the contrary, a less significant but discernible trend towards a further bone loss was apparent in the BMD values measured 6 months after the end of therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
T Nencioni; M Penotti; M Barbieri-Carones; S Ortolani; C Trevisan; F Polvani
Related Documents :
11094996 - Percutaneous cementoplasty for pelvic bone metastasis.
18852226 - Changes in body composition after glucocorticoid therapy in patients with systemic lupu...
22906376 - European college of orthodontics: commission on membership and tenure.
14583776 - Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma...
22122836 - Postoperative improvement in health-related quality of life: a national comparison of s...
15662626 - Analysis of hyperpigmentation and hypopigmentation after er:yag laser skin resurfacing.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology     Volume:  5     ISSN:  0951-3590     ISO Abbreviation:  Gynecol. Endocrinol.     Publication Date:  1991 Mar 
Date Detail:
Created Date:  1991-10-24     Completed Date:  1991-10-24     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8807913     Medline TA:  Gynecol Endocrinol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  49-56     Citation Subset:  IM    
I Obstetrical and Gynaecological Department, University of Milano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amenorrhea / chemically induced
Bone Density / drug effects*
Buserelin / adverse effects,  pharmacology*
Endometriosis / drug therapy
Estradiol / blood
Follicle Stimulating Hormone / blood
Luteinizing Hormone / blood
Middle Aged
Time Factors
Uterine Neoplasms / drug therapy
Reg. No./Substance:
50-28-2/Estradiol; 57982-77-1/Buserelin; 9002-67-9/Luteinizing Hormone; 9002-68-0/Follicle Stimulating Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Combined growth hormone and gonadotropin treatment for ovulation induction in patients with non-resp...
Next Document:  Ovulation induction with human menopausal gonadotropins--a changing scene.